Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Daniela Maurici is active.

Publication


Featured researches published by Daniela Maurici.


The New England Journal of Medicine | 1995

Expression of P-Glycoprotein in High-Grade Osteosarcomas in Relation to Clinical Outcome

Nicola Baldini; Katia Scotlandi; Giovanni Barbanti-Bròdano; Maria Cristina Manara; Daniela Maurici; Gaetano Bacci; Franco Bertoni; Piero Picci; Sandra Sottili; Mario Campanacci; Massimo Serra

BACKGROUND Increased levels of P-glycoprotein occur in some osteosarcomas. In this study we determined the relation between P-glycoprotein status and outcome in patients with high-grade osteosarcoma. METHODS P-glycoprotein status was determined immunohistochemically in specimens of osteosarcoma of the extremities (stage II) from 92 patients who were treated with surgery and chemotherapy. The P-glycoprotein status was analyzed in relation to the length of event-free survival. RESULTS The presence of increased levels of P-glycoprotein in the osteosarcoma was significantly associated with a decreased probability of remaining event-free after diagnosis (P = 0.002). In a multivariate analysis, P-glycoprotein status (P = 0.001) and the extent of tumor necrosis after preoperative chemotherapy (P = 0.04) were independent predictors of clinical outcome. The risk of adverse events was increased substantially (rate ratio, 3.37; 95 percent confidence interval, 1.60 to 7.10) among patients with increased levels of P-glycoprotein in tumor cells, as compared with patients who did not have increased levels of P-glycoprotein in tumor cells. CONCLUSIONS In patients with high-grade osteosarcoma treated with surgery and chemotherapy, the presence of increased levels of P-glycoprotein in tumor cells is associated with a significantly increased risk of adverse events and is independent of the extent of necrosis after preoperative chemotherapy.


Cancer | 1995

Clinical relevance of Ki-67 expression in bone tumors

Katia Scotlandi; Massimo Serra; M. Cristina Manara; Daniela Maurici; Stefania Benini; Giuseppe Nini; Mario Campanacci; Nicola Baldini

Background. The availability of Ki‐67 monoclonal antibody has opened new possibilities for an extensive analysis of cell kinetics in human neoplasms. Ki‐67 antibody reveals a nuclear antigen that is expressed in proliferating but not in quiescent cells. Although the reliability of Ki‐67 immunostaining has been evaluated in different tumor types, little information has been reported on bone neoplasms.


Cancer Genetics and Cytogenetics | 1998

Frequency and implications of chromosome 8 and 12 gains in Ewing sarcoma

Daniela Maurici; Antonio R. Perez-Atayde; Holcombe E. Grier; Nicola Baldini; Massimo Serra; Jonathan A. Fletcher

Ewing sarcoma (ES) is the second most common primary malignant tumor of bone in children and young adolescents. Most ES contain a pathognomonic translocation t(11;22)(q24;q12) that is likely a pivotal event in the tumorigenesis of these neoplasms. Many ES also contain nonrandom, numerical chromosomal aberrations, the most common of which are trisomies 8 and 12. In this study we evaluated the hypothesis that these trisomies might occur during neoplastic progression and might be associated with differences in biologic behavior. We tested this hypothesis using a combined cytogenetic and dual color fluorescence in situ hybridization approach to determine chromosome 8 and 12 copy number in 52 ES. Relative gains, primarily trisomies, of chromosomes 8 and 12 were found in 24 (46%) and 17 (33%) cases, respectively. Trisomy 8 and trisomy 12 were independent events acquired in a flexible order during ES genetic progression. Our preliminary findings also suggest a higher frequency of trisomies 8 and 12 in relapses than in primary tumors. Prospective studies will be required to determine whether either trisomy is prognostic in newly-diagnosed ES.


European Journal of Cancer | 1995

Analysis of P-glycoprotein expression in osteosarcoma

Massimo Serra; K. Scotlandi; Maria Cristina Manara; Daniela Maurici; Stefania Benini; Manuela Sarti; Mario Campanacci; Nicola Baldini

Current treatment of high-grade osteosarcoma combines surgical removal of the lesion with chemotherapy. In this study we evaluated whether the expression of P-glycoprotein, a protein closely associated with multidrug resistance, may be helpful in identifying the patients whose tumours will be further resistant to specific agents. By using multidrug-resistant osteosarcoma cell lines as standards, the expression of P-glycoprotein was evaluated in 105 cases of primary and metastatic osteosarcoma by semiquantitative immunofluorescence. Overexpression of the protein was shown in 23% of primary and in 50% of metastatic lesions. In 38 cases, homogeneously treated and followed-up for at least 24 months, overexpression of P-glycoprotein appeared to be associated with a higher relapse rate and with a trend toward a worse outcome. These data support the role of P-glycoprotein in the response to chemotherapy and its involvement in the determination of the outcome of osteosarcoma patients.


Oncogene | 1999

The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells

Katia Scotlandi; Maria Cristina Manara; Massimo Serra; Stefania Benini; Daniela Maurici; Antonella Caputo; Carla De Giovanni; Pier Luigi Lollini; Patrizia Nanni; Piero Picci; Mario Campanacci; Nicola Baldini

The relationship between P-glycoprotein expression and malignancy is controversial. We have recently found that, in osteosarcoma, multidrug resistance (MDR) is associated with a less aggressive behavior, both in vitro and in clinical settings. In this study, we evaluated whether P-glycoprotein overexpression has a cause-effect relationship with the reduced metastatic potential of MDR cells, or rather reflects a more complex phenotype. MDR1 gene-transfected osteosarcoma cell clones, showing different levels of P-glycoprotein expression, were analysed for their in vitro characteristics and their tumorigenic and metastatic ability in athymic mice. Apart from the different levels of P-glycoprotein, no significant change in the expression of surface antigens or in the differentiative features were observed in the MDR1 gene transfectants compared to the parental cell lines or control clones, obtained by transfection with neo gene alone. In contrast to controls, however, MDR1 transfectants showed a significantly lower ability to grow in semi-solid medium and were completely unable to grow and give lung metastases in athymic mice. These findings indicate that P-glycoprotein overexpression is causally associated with a low malignant potential of osteosarcoma cells, and open new insights on the role and functions of P-glycoprotein activity.


Bone | 2000

Reversal of malignant phenotype in human osteosarcoma cells transduced with the alkaline phosphatase gene.

Maria Cristina Manara; Nicola Baldini; Massimo Serra; Pier Luigi Lollini; C. De Giovanni; Monica Vaccari; A Argnani; Stefania Benini; Daniela Maurici; Piero Picci; K. Scotlandi

Alkaline phosphatases are a family of glycoproteins that are able to hydrolize various monophosphate esters at a high pH optimum. Liver/bone/kidney (L/B/K) alkaline phosphatase (ALP) is one of the four major isoenzymes that belong to this family. Apart from its role in normal bone mineralization, other functions of L/B/K ALP remain obscure, both in physiological and in neoplastic conditions, including the bone-forming tumor osteosarcoma. In this study, we transfected the U-2 OS osteosarcoma cell line, which does not show any basal expression of this enzyme, with the full-length gene of L/B/K ALP, and analyzed the in vitro and in vivo features of four transfectants showing different expression of L/B/K ALP. A reduced in vitro ability to invade Matrigel and to grow in a semi-solid medium, together with a lower tumorigenic and metastatic ability in athymic mice, was found to be associated with a high level of cell surface L/B/K ALP activity. Moreover, L/B/K ALP transfectants showed a reduced secretion of matrix metalloproteinase-9 enzyme. These findings indicate a loss of aggressiveness of osteosarcoma cells after the expression of L/B/K ALP on their surface and suggest a new role for this enzyme.


Journal of Cancer Research and Clinical Oncology | 1992

Adriamycin binding assay: a valuable chemosensitivity test in human osteosarcoma

Nicola Baldini; Katia Scotlandi; Massimo Serra; Katsuyuki Kusuzaki; Toshiharu Shikita; Maria Cristina Manara; Daniela Maurici; Mario Campanacci

SummaryThe reliability of a simple method evaluating the pattern of subcellular binding of Adriamycin (Adriamycin binding assay, ABA) as an index of sensitivity was demonstrated in different primary cultures and in sensitive and resistant cell lines of human osteosarcoma. After exposure to Adriamycin (10 μg/ml for 30 min at 37°C), living sensitive cells showed selective intranuclear uptake of the drug, whereas in resistant cells no distinct subcellular distribution was observed. The binding pattern of Adriamycin in sensitive and in highly resistant cells was inversely related to the expression of P-glycoprotein. However, low levels of resistance in vitro, not detectable by increased levels of expression of P-glycoprotein, were revealed by ABA. The use of ABA in combination with the estimate of P-glycoprotein expression is recommended in clinical practice as an accurate means for predicting the sensitivity of osteosarcoma to Adriamycin.


Cytotechnology | 1996

Evaluation of P-glycoprotein expression in soft tissue sarcomas of the extremities

Massimo Serra; Katia Scotlandi; Maria Cristina Manara; Daniela Maurici; Stefania Benini; Manuela Sarti; Giuseppe Nini; Giovanni Barbanti-Bròdano; Nicola Baldini

Soft tissue sarcomas comprise a heterogeneous group of mesenchymal tumors accounting for less than one-percent of adult neoplasms. In the last few years, the use of adjuvant chemotorapy has been proposed for the treatment of these lesions in order to obain a better systemic control, but its usefulness is still controversial. In this study, we evaluated whether P-glycoprotein, a membrane protein strictly associated with multidrug resistance, is overexpressed in soft tissue sarcomas. By using human multidrug resistant sarcoma cell lines as controls, we analyzed P-glycoprotein expression in 34 primary and in 23 relapsed soft tissue sarcomas of the extremities. Overexpression of P-glycoprotein was found in 6 out of 34 primaries (18%) and in 8 out of 23 relapses (35%). In particular, in malignant fibrous histiocytoma, the most frequent soft tissue sarcoma of adults, P-glycoprotein overexpression was found in 23% of primary untreated cases, in agreement with the reported relapse rate of this tumor after surgery and chemotherapy. These data suggest that, in soft tissue sarcomas, overexpression of P-glycoprotein may be of prognostic value and that the assessment of P-glycoprotein expression may be useful for the design of chemotherapy protocols.


Cancer Research | 1996

Insulin-like Growth Factor I Receptor-mediated Circuit in Ewing's Sarcoma/Peripheral Neuroectodermal Tumor: A Possible Therapeutic Target

Katia Scotlandi; Stefania Benini; Manuela Sarti; Massimo Serra; Pier Luigi Lollini; Daniela Maurici; Piero Picci; Maria Cristina Manara; Nicola Baldini


Human Pathology | 1996

Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor.

K. Scotlandi; Massimo Serra; Maria Cristina Manara; Stefania Benini; Manuela Sarti; Daniela Maurici; Pier Luigi Lollini; Piero Picci; Franco Bertoni; Nicola Baldini

Collaboration


Dive into the Daniela Maurici's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge